Drug details

Lumoxiti (moxetumomab pasudotox-tdfk for injection)

type of Antineoplastics Monoclonal Antibody

Lumoxiti (moxetumomab pasudotox-tdfk) is a CD22-directed cytotoxin indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).

This drug may have the following side effects:

• nausea,
• diarrhea,
• fever,
• constipation,
• headache,
• fatigue,
• anemia,
• infusion related reactions,

The following drugs are related to Lumoxiti, either as a replacement or used together:

• Besponsa (inotuzumab ozogamicin injection)
• Blincyto (blinatumomab for injection)
• Clolar (clofarabine)
• Sprycel (dasatinib)
• Gleevec (imatinib mesylate)
• Iclusig (ponatinib tablets)
• Kymriah (tisagenlecleucel suspension for intravenous infusion)
• Marqibo (vincristine sulfate liposome injection)
• Monjuvi (tafasitamab-cxix injection)
• Oncaspar (pegaspargase)
• Vincristine Sulfate Injection (vincristine sulfate)